Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b study of Stribild versus ritonavir-boosted atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive women with HIV-1
2012-003708-11Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of emtricitabine + elvitegravir + cobicistat + tenofovir disoproxil, atazanavir, ritonavir, emtricitabine, tenofovir disoproxil fumarate in Human immunodeficiency virus infection type 1, sponsored by Gilead Sciences. Started Oct 2012; status: completed.
02
Drugs
emtricitabine + elvitegravir + cobicistat + tenofovir disoproxilatazanavirritonaviremtricitabinetenofovir disoproxil fumarate
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2012-003708-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003708-11.